Araki, Kazuhiro
Ito, Yoshinori
Fukada, Ippei
Kobayashi, Kokoro
Miyagawa, Yoshimasa
Imamura, Michiko
Kira, Ayako
Takatsuka, Yuichi
Egawa, Chiyomi
Suwa, Hirofumi
Ohno, Shinji
Miyoshi, Yasuo
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP16K1048)
Article History
Received: 9 April 2018
Accepted: 2 October 2018
First Online: 16 October 2018
Ethics approval and consent to participate
: The study was conducted in accordance with the guidelines for Good Clinical Practice and the Declaration of Helsinki. Written informed consent was obtained from each participant before undertaking any study-related procedures. This study was approved by the ethics committee of The Cancer Institute Hospital of the Japanese Foundation for Cancer Research (#2013–1096 and #2017–1076) and the Hyogo College of Medicine (No. 1061 and No. 2720).
: Not applicable.
: K Araki has performed contracted research for Eisai, Novartis, and AstraZeneca. Y Ito has performed contracted research for Chugai, Parexel, and Eisai. S Ohno has performed contracted research for Chugai and AstraZeneca. Y Miyoshi has received research funding and honoraria from Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., and TAIHO PHARMACEUTICAL Co., Ltd., AstraZeneca plc, Novartis Pharma K.K., Pfizer Japan Inc., MSD K.K. Eli Lilly Japan K.K., Kyowa Hakko Kirin Co., Ltd., and DAIICHI SANKYO Co., Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.